Literature DB >> 7844467

Escherichia coli heat-stable enterotoxins, guanylins, and their receptors: what are they and what do they do?

R A Giannella1.   

Abstract

STa represents a family of homologous heat-stable peptide toxins that are elaborated by a variety of bacteria capable of causing enteric disease in human beings. All these peptides have a tertiary structure, maintained by disulfide bridges, which is required for receptor occupancy and biologic activity. The toxins have highly homologous carboxy-terminal domains and variable differences at the amino-terminal domain. The amino-terminal domain of these various peptides is not required for biologic activity. Recently an endogenous ligand called guanylin has been extracted from mammalian intestine and shown to bind the STa receptor. A similar peptide, called uroguanylin, has been found in human and animal urine. It is likely that guanylin and uroguanylin are indeed endogenous ligands for the STa receptor and may be modulators of Cl- secretion in the intestine, kidney, and perhaps in other organs. The STa-guanylin receptors are located on enterocytes, colonocytes, and various extraintestinal tissues. These receptors are one of a family of transmembrane guanylate cyclases that have homologous intracytoplasmic domains but divergent extracellular domains. It is likely that the extracellular domains of these various receptor cyclases confer specificity for ligand binding. Although GC-C, the STa receptor, may also be a receptor for guanylin, other receptors may exist that may be more specific for guanylin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844467

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

Review 1.  E. coli heat-stable enterotoxin and guanylyl cyclase C: new functions and unsuspected actions.

Authors:  Ralph A Giannella; Elizabeth A Mann
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

Review 2.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

3.  Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity.

Authors:  F K Hamra; S L Eber; D T Chin; M G Currie; L R Forte
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

4.  Role of the prosequence of guanylin.

Authors:  A Schulz; U C Marx; Y Hidaka; Y Shimonishi; P Rösch; W G Forssmann; K Adermann
Journal:  Protein Sci       Date:  1999-09       Impact factor: 6.725

Review 5.  Irritable bowel syndrome: recent and novel therapeutic approaches.

Authors:  Viola Andresen; Michael Camilleri
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Can colorectal cancer be prevented or treated by oral hormone replacement therapy?

Authors:  P Li; J E Lin; S Schulz; G M Pitari; S A Waldman
Journal:  Curr Mol Pharmacol       Date:  2009-11       Impact factor: 3.339

Review 7.  Current and novel therapeutic options for irritable bowel syndrome management.

Authors:  M Camilleri; V Andresen
Journal:  Dig Liver Dis       Date:  2009-08-08       Impact factor: 4.088

8.  Phosphorylation and activation of the intestinal guanylyl cyclase receptor for Escherichia coli heat-stable toxin by protein kinase C.

Authors:  J K Crane; K L Shanks
Journal:  Mol Cell Biochem       Date:  1996-12-20       Impact factor: 3.396

Review 9.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

10.  Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells.

Authors:  Giovanni M Pitari; Jieru E Lin; Fawad J Shah; Wilhelm J Lubbe; David S Zuzga; Peng Li; Stephanie Schulz; Scott A Waldman
Journal:  Carcinogenesis       Date:  2008-06-19       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.